Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 97

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

In Vitro Activities of Nisin and Nisin Derivatives Alone and In Combination with Antibiotics against Staphylococcus Biofilms

Field, Des, O’ Connor, Rory, Cotter, Paul D., Ross, R. Paul, Hill, Colin · 2016 · Frontiers in Microbiology

Abstract

The development and spread of pathogenic bacteria that are resistant to the existing catalog of antibiotics is a major public health threat. Biofilms are complex, sessile communities of bacteria embedded in an organic polymer matrix which serve to further enhance antimicrobial resistance. Consequently, novel compounds and innovative methods are urgently required to arrest the proliferation of drug-resistant infections in both nosocomial and community environments. Accordingly, it has been suggested that antimicrobial peptides could be used as novel natural inhibitors that can be used in formulations with synergistically acting antibiotics. Nisin is a member of the lantibiotic family of antimicrobial peptides that exhibit potent antibacterial activity against many Gram-positive bacteria. Recently we have used bioengineering strategies to enhance the activity of nisin against several high profile targets, including multi-drug resistant clinical pathogens such as methicillin-resistant Staphylococcus aureus, vancomycin-resistant enterococci, staphylococci, and streptococci associated with bovine mastitis. We have also identified nisin derivatives with an enhanced ability to impair biofilm formation and to reduce the density of established biofilms of methicillin resistant S. pseudintermedius. The present study was aimed at evaluating the potential of nisin and nisin derivatives to increase the efficacy of conventional antibiotics and to assess the possibility of killing and/or eradicating biofilm-associated cells of a variety of staphylococcal targets. Growth curve-based comparisons established that combinations of derivatives nisin V + penicillin or nisin I4V + chloramphenicol had an enhanced inhibitory effect against S. aureus SA113 and S. pseudintermedius DSM21284, respectively, compared to the equivalent nisin A + antibiotic combinations or when each antimicrobial was administered alone. Furthermore, the metabolic activity of established biofilms treated with nisin V + chloramphenicol and nisin I4V + chloramphenicol combinations revealed a significant decrease in S. aureus SA113 and S. pseudintermedius DSM21284 biofilm viability, respectively, compared to the nisin A + antibiotic combinations as determined by the rapid colorimetric XTT assay. The results indicate that the activities of the nisin derivative and antibiotic combinations represent a significant improvement over that of the wild-type nisin and antibiotic combination and merit further investigation with a view to their use as anti-biofilm agents.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3389/fmicb.2016.00508

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Figures

FIGURE 1 Growth curve analysis of Staphylococcus aureus SA113 in the presence of nisin A (A), nisin V (V), and nisin I4V (I4V) peptides (0.937 μM; 3.0 μg/ml) and in combination with 1.5 μg/ml chloramphenicol (Cm), 5.0 μg/ml vancomycin (Van) and 0.005 μg/ml penicillin (Pen). The means and standard deviations of three independent determinations are presented.
FIGURE 1 Growth curve analysis of Staphylococcus aureus SA113 in the presence of nisin A (A), nisin V (V), and nisin I4V (I4V) peptides (0.937 μM; 3.0 μg/ml) and in combination with 1.5 μg/ml chloramphenicol (Cm), 5.0 μg/ml vancomycin (Van) and 0.005 μg/ml penicillin (Pen). The means and standard deviations of three independent determinations are presented.CC BY · PubMed Central
FIGURE 2 Growth curve analysis of S. pseudintermedius DSM21284 in the presence of nisin A (A), nisin V (V), and nisin I4V (I4V) peptides (0.292 μM; 0.932 μg/ml) and in combination with 0.8 μg/ml penicillin (Pen), 3.0 μg/ml chloramphenicol (Cm), 0.5 μg/ml vancomycin (Van), and 4.0 μg/ml erythromycin (Ery). The means and standard deviations of three independent determinations are presented.
FIGURE 2 Growth curve analysis of S. pseudintermedius DSM21284 in the presence of nisin A (A), nisin V (V), and nisin I4V (I4V) peptides (0.292 μM; 0.932 μg/ml) and in combination with 0.8 μg/ml penicillin (Pen), 3.0 μg/ml chloramphenicol (Cm), 0.5 μg/ml vancomycin (Van), and 4.0 μg/ml erythromycin (Ery). The means and standard deviations of three independent determinations are presented.CC BY · PubMed Central
FIGURE 3 Growth curve analysis of S. aureus ST528 (MRSA) in the presence of nisin A (A), nisin V (V), and nisin I4V (I4V) peptides (0.2 μM) and in combination with 10 μg/ml streptomycin (Str), 2.5 μg/ml chloramphenicol (Cm) and 0.2 μg/ml vancomycin (Van). The means and standard deviations of three independent determinations are presented.
FIGURE 3 Growth curve analysis of S. aureus ST528 (MRSA) in the presence of nisin A (A), nisin V (V), and nisin I4V (I4V) peptides (0.2 μM) and in combination with 10 μg/ml streptomycin (Str), 2.5 μg/ml chloramphenicol (Cm) and 0.2 μg/ml vancomycin (Van). The means and standard deviations of three independent determinations are presented.CC BY · PubMed Central
FIGURE 4 Viability of biofilms of (A)S. aureus SA113 untreated, and treated with 6X MIC (15μM) of nisin A, nisin V (M21V), and nisin I4V and peptides alone and in combination with 2X MIC chloramphenicol for 24 h and (B)S. pseudintermedius DSM 21284 treated with 4X MIC (1.25 μM) of nisin A, nisin V (M21V), and nisin I4V peptides alone and in combination with 1X MIC chloramphenicol for 24 h as evaluated by XTT (2,3-bis[2-methyloxy-4-nitro-5-sulfophenyl]-2H-tetrazolium-5-carboxanilide) assay measured using a microtiter plate reader. The means and standard deviations of triplicate determinations are presented. Asterisks indicate statistically significant differences (Student’s t-test) between peptide and antibiotic combinations used at similar concentration (∗∗∗p < 0.001).
FIGURE 4 Viability of biofilms of (A)S. aureus SA113 untreated, and treated with 6X MIC (15μM) of nisin A, nisin V (M21V), and nisin I4V and peptides alone and in combination with 2X MIC chloramphenicol for 24 h and (B)S. pseudintermedius DSM 21284 treated with 4X MIC (1.25 μM) of nisin A, nisin V (M21V), and nisin I4V peptides alone and in combination with 1X MIC chloramphenicol for 24 h as evaluated by XTT (2,3-bis[2-methyloxy-4-nitro-5-sulfophenyl]-2H-tetrazolium-5-carboxanilide) assay measured using a microtiter plate reader. The means and standard deviations of triplicate determinations are presented. Asterisks indicate statistically significant differences (Student’s t-test) between peptide and antibiotic combinations used at similar concentration (∗∗∗p < 0.001).CC BY · PubMed Central
FIGURE 5 Live/dead staining confocal images of S. pseudintermedius DSM21284 biofilms (A) untreated, (B) chloramphenicol (Cm) 1X MIC (8 μg/ml), (C) nisin A 4X MIC (1.25 μM), (D) Nisin V (M21V) 4X MIC (1.25 μM), (E) nisin I4V 4X MIC (1.25 μM), (F) nisin A + Cm, (G) nisin V + Cm, and (H) nisin I4V + Cm.
FIGURE 5 Live/dead staining confocal images of S. pseudintermedius DSM21284 biofilms (A) untreated, (B) chloramphenicol (Cm) 1X MIC (8 μg/ml), (C) nisin A 4X MIC (1.25 μM), (D) Nisin V (M21V) 4X MIC (1.25 μM), (E) nisin I4V 4X MIC (1.25 μM), (F) nisin A + Cm, (G) nisin V + Cm, and (H) nisin I4V + Cm.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 3 references

Research works printed but not linked: 57

  1. Archer, 2011, Staphylococcus aureus biofilms: properties, regulation, and roles in human disease., Virulence, 2, 445, 10.4161/viru.2.5.17724 · DOI · Paper page
  2. Bierbaum, 2009, Lantibiotics: mode of action, biosynthesis and bioengineering., Curr. Pharm. Biotechnol., 10, 2, 10.2174/138920109787048616 · DOI · Paper page
  3. Breukink, 1999, The lantibiotic nisin, a special case or not?, Biochim. Biophys. Acta, 1462, 223, 10.1016/S0005-2736(99)00208-4 · DOI · Paper page
  4. Brumfitt, 2002, Nisin, alone and combined with peptidoglycan-modulating antibiotics: activity against methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococci., J. Antimicrob. Chemother., 50, 731, 10.1093/jac/dkf190 · DOI · Paper page
  5. Buommino, 2014, Recent advances in natural product-based anti-biofilm approaches to control infections., Mini Rev. Med. Chem., 14, 1169, 10.2174/1389557515666150101095853 · DOI
  6. Cavera, 2015a, Bacteriocins and their position in the next wave of conventional antibiotics., Int. J. Antimicrob. Agents, 46, 494, 10.1016/j.ijantimicag.2015.07.011 · DOI · Paper page
  7. Cavera, 2015b, The natural antimicrobial subtilosin a synergizes with lauramide arginine ethyl Ester (LAE), epsilon-Poly-L-lysine (Polylysine), Clindamycin Phosphate and Metronidazole, Against the Vaginal Pathogen Gardnerella vaginalis., Probiotics Antimicrob Proteins, 7, 164, 10.1007/s12602-014-9183-1 · doi:10.1007/s12602-014-9183-1
  8. Chatterjee, 2005, Biosynthesis and mode of action of lantibiotics., Chem. Rev., 105, 633, 10.1021/cr030105v · DOI · Paper page
  9. Corbin, 2011, Antimicrobial penetration and efficacy in an in vitro oral biofilm model., Antimicrob. Agents Chemother., 55, 3338, 10.1128/AAC.00206-11 · DOI
  10. Cotter, 2005a, Bacterial lantibiotics: strategies to improve therapeutic potential., Curr. Protein Pept. Sci., 6, 61, 10.2174/1389203053027584 · DOI · Paper page
  11. Cotter, 2013, Bacteriocins - a viable alternative to antibiotics?, Nat. Rev. Microbiol., 11, 95, 10.1038/nrmicro2937 · DOI · Paper page
  12. Cramton, 1999, The Intercellular Adhesion (ica) locus is present in Staphylococcus aureus and Is Required for Biofilm Formation., Infect. Immun., 67, 5427, 10.1128/IAI.67.10.5427-5433.1999 · DOI · Paper page
  13. Darouiche, 1994, Vancomycin penetration into biofilm covering infected prostheses and effect on bacteria., J. Infect. Dis., 170, 720, 10.1093/infdis/170.3.720 · DOI · Paper page
  14. Davison, 2010, Spatial and temporal patterns of biocide action against Staphylococcus epidermidis biofilms., Antimicrob. Agents Chemother., 54, 2920, 10.1128/AAC.01734-09 · DOI
  15. Delves-Broughton, 1996, Applications of the bacteriocin, nisin., Antonie Van Leeuwenhoek, 69, 193, 10.1007/BF00399424 · DOI · Paper page
  16. Devriese, 2005, Staphylococcus pseudintermedius sp. nov., a coagulase-positive species from animals., Int. J. Syst. Evol. Microbiol., 55, 1569, 10.1099/ijs.0.63413-0 · DOI · Paper page
  17. Dosler, 2011, In vitro activities of nisin alone or in combination with vancomycin and ciprofloxacin against methicillin-resistant and methicillin-susceptible Staphylococcus aureus Strains., Chemotherapy, 57, 511, 10.1159/000335598 · DOI · Paper page
  18. Dosler, 2012, In vitro activities of antimicrobial cationic peptides; melittin and nisin, alone or in combination with antibiotics against Gram-positive bacteria., J. Chemother., 24, 137, 10.1179/1973947812y.0000000007 · DOI
  19. Dosler, 2013, In vitro pharmacokinetics of antimicrobial cationic peptides alone and in combination with antibiotics against methicillin resistant Staphylococcus aureus biofilms., Peptides, 49, 53, 10.1016/j.peptides.2013.08.008 · DOI
  20. Field, 2012, Bioengineered nisin a derivatives with enhanced activity against both gram positive and gram negative pathogens., PLoS ONE, 7, 10.1371/journal.pone.0046884 · DOI · Paper page
  21. Field, 2015a, Bioengineering of the model lantibiotic nisin., Bioengineered, 6, 187, 10.1080/21655979.2015.1049781 · DOI
  22. Field, 2015b, A Bioengineered nisin derivative to control biofilms of Staphylococcus pseudintermedius., PLoS ONE, 10, 10.1371/journal.pone.0119684 · DOI
  23. Field, 2008, The generation of nisin variants with enhanced activity against specific gram-positive pathogens., Mol. Microbiol., 69, 218, 10.1111/j.1365-2958.2008.06279.x · DOI · Paper page
  24. Field, 2010, Studies with bioengineered Nisin peptides highlight the broad-spectrum potency of Nisin V., Microb Biotechnol., 3, 473, 10.1111/j.1751-7915.2010.00184.x · DOI
  25. Fitzgerald, 1997, Fine-structure molecular epidemiological analysis of Staphylococcus aureus recovered from cows., Epidemiol. Infect., 119, 261, 10.1017/S0950268897007802 · doi:10.1017/s0950268897007802
  26. Flemming, 2010, The biofilm matrix., Nat. Rev. Micro, 8, 623, 10.1038/nrmicro2415 · DOI · Paper page
  27. Giacometti, 2000, In-vitro activity and killing effect of polycationic peptides on methicillin-resistant Staphylococcus aureus and interactions with clinically used antibiotics., Diagn Microbiol. Infect Dis., 38, 115, 10.1016/S0732-8893(00)00175-9 · DOI
  28. Hájek, 1976, Staphylococcus intermedius, a new species isolated from animals., Int. J. Syst. Bacteriol., 26, 401, 10.1099/00207713-26-4-401 · doi:10.1099/00207713-26-4-401
  29. Jain, 2009, Biofilm production, a marker of pathogenic potential of colonizing and commensal staphylococci., J. Microbiol. Methods, 76, 88, 10.1016/j.mimet.2008.09.017 · doi:10.1016/j.mimet.2008.09.017
  30. Kelly, 2012, Prevention of Staphylococcus aureus biofilm formation and reduction in established biofilm density using a combination of phage K and modified derivatives., Lett. Appl. Microbiol., 54, 286, 10.1111/j.1472-765X.2012.03205.x · DOI
  31. Kneuper, 2014, Heterogeneity in ess transcriptional organization and variable contribution of the Ess/Type VII protein secretion system to virulence across closely related Staphylocccus aureus strains., Mol. Microbiol., 93, 928, 10.1111/mmi.12707 · DOI
  32. Kong, 2014, Cloning and optimization of a nisin biosynthesis pathway for bacteriocin harvest., ACS Synth. Biol., 3, 439, 10.1021/sb500225r · DOI
  33. Kristian, 2003, Alanylation of teichoic acids protects Staphylococcus aureus against Toll-like receptor 2-dependent host defense in a mouse tissue cage infection model., J. Infect. Dis., 188, 414, 10.1086/376533 · DOI
  34. Lebel, 2013, Antimicrobial activity of nisin against the swine pathogen Streptococcus suis and its synergistic interaction with antibiotics., Peptides, 50, 19, 10.1016/j.peptides.2013.09.014 · doi:10.1016/j.peptides.2013.09.014
  35. Livermore, 2000, Antibiotic resistance in staphylococci., Int. J. Antimicrob. Agents, 16(Suppl. 1), S3, 10.1016/S0924-8579(00)00299-5 · DOI · Paper page
  36. Mataraci, 2012, In vitro activities of antibiotics and antimicrobial cationic peptides alone and in combination against methicillin-resistant Staphylococcus aureus biofilms., Antimicrob. Agents Chemother., 56, 6366, 10.1128/AAC.01180-12 · DOI
  37. Molloy, 2013, Saturation mutagenesis of lysine 12 leads to the identification of derivatives of nisin A with enhanced antimicrobial activity., PLoS ONE, 8, 10.1371/journal.pone.0058530 · DOI
  38. Murayama, 2013, In vitro antiseptic susceptibilities for Staphylococcus pseudintermedius isolated from canine superficial pyoderma in Japan., Vet. Dermatol., 24, 126, 10.1111/j.1365-3164.2012.01103.x · doi:10.1111/j.1365-3164.2012.01103.x
  39. Naghmouchi, 2012, Antibiotic and antimicrobial peptide combinations: synergistic inhibition of Pseudomonas fluorescens and antibiotic-resistant variants., Res Microbiol, 163, 101, 10.1016/j.resmic.2011.11.002 · DOI
  40. Okuda, 2013, Effects of bacteriocins on methicillin-resistant Staphylococcus aureus biofilm., Antimicrob. Agents Chemother., 57, 5572, 10.1128/AAC.00888-13 · DOI · Paper page
  41. O’Toole, 2011, Microtiter dish biofilm formation assay., J. Vis. Exp., 30, 10.3791/2437 · DOI · Paper page
  42. Otto, 2008, Staphylococcal biofilms., Curr. Top. Microbiol. Immunol., 322, 207
  43. Paul, 2011, Carriage of methicillin-resistant Staphylococcus pseudintermedius in small animal veterinarians: indirect evidence of zoonotic transmission., Zoo. Public Health, 58, 533, 10.1111/j.1863-2378.2011.01398.x · DOI · Paper page
  44. Piper, 2009a, Discovery of medically significant lantibiotics., Curr. Drug Discov. Technol., 6, 1, 10.2174/157016309787581075 · DOI
  45. Piper, 2009b, A comparison of the activities of lacticin 3147 and nisin against drug-resistant Staphylococcus aureus and Enterococcus species., J. Antimicrob Chemother., 64, 546, 10.1093/jac/dkp221 · DOI · Paper page
  46. Rishi, 2014, Evaluation of nisin-beta-lactam antibiotics against clinical strains of Salmonella enterica serovar Typhi., J. Antibiot. (Tokyo), 67, 807, 10.1038/ja.2014.75 · doi:10.1038/ja.2014.75
  47. Ruscher, 2009, Prevalence of Methicillin-resistant Staphylococcus pseudintermedius isolated from clinical samples of companion animals and equidaes., Vet. Microbiol., 136, 197, 10.1016/j.vetmic.2008.10.023 · DOI · Paper page
  48. Scheffers, 2015, LipidII: just another brick in the wall?, PLoS Pathog., 11, 10.1371/journal.ppat.1005213 · doi:10.1371/journal.ppat.1005213
  49. Sears, 1992, Evaluation of a nisin-based germicidal formulation on teat skin of live cows., J. Dairy Sci., 75, 3185, 10.3168/jds.S0022-0302(92)78083-7 · doi:10.3168/jds.s0022-0302(92)78083-7
  50. Singh, 2013, Characterization of the biofilm forming ability of Staphylococcus pseudintermedius from dogs., BMC Vet. Res., 9, 10.1186/1746-6148-9-93 · doi:10.1186/1746-6148-9-93
  51. Stepanović, 2007, Quantification of biofilm in microtiter plates: overview of testing conditions and practical recommendations for assessment of biofilm production by staphylococci., APMIS, 115, 891, 10.1111/j.1600-0463.2007.apm_630.x · DOI · Paper page
  52. Stryjewski, 2014, Methicillin-resistant Staphylococcus aureus: an evolving pathogen., Clin. Infect. Dis., 58(Suppl. 1), S10, 10.1093/cid/cit613 · DOI · Paper page
  53. Tong, 2014, An in vitro study on the effects of nisin on the antibacterial activities of 18 antibiotics against Enterococcus faecalis., PLoS ONE, 9, 10.1371/journal.pone.0089209 · DOI
  54. Viguier, 2009, Mastitis detection: current trends and future perspectives., Trends Biotechnol., 27, 486, 10.1016/j.tibtech.2009.05.004 · DOI · Paper page
  55. Wu, 2007, Therapeutic effect of nisin Z on subclinical mastitis in lactating cows., Antimicrob. Agents Chemother., 51, 3131, 10.1128/AAC.00629-07 · DOI
  56. Yoo, 2010, High prevalence of Fluoroquinolone- and Methicillin-resistant Staphylococcus pseudintermedius isolates from canine pyoderma and otitis externa in veterinary teaching hospital., J. Microbiol. Biotechnol., 20, 798
  57. Yoon, 2010, Antibiotic resistance profiles of Staphylococcus pseudintermedius isolates from canine patients in Korea., J. Microbiol. Biotechnol., 20, 1764

Cited by

Metadata

Authors
Field, D., O’ Connor, R., Cotter, P. D., Ross, R. P., & Hill, C.
Venue
Frontiers in Microbiology
Published
2016-04-18
Volume
7
ISSN
1664-302X
Cited by
97
References
3
Funders
Science Foundation Ireland (10/IN.1/B3027, 14/TIDA/2286, 11/PI/1137, SFI/12/RC/2273)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.